Home›Clinical trials›California

GLP-1 clinical trials in California: 51 recruiting now

By John Samaras, EditorRegistry checked September 4, 2026

51 GLP-1 clinical trials are recruiting at 192 sites in 72 cities across California. Every site below is listed with its city and, where the sponsor publishes one, the number to call.

Every study recruiting in California

  1. A Phase 4, Prospective, Open-Label, Single-Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab

    Phase 4. Run by Eli Lilly and Company. Registry number NCT06864026.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people ease psoriatic arthritis.

    Who can join. Adults 18+, have psoriatic arthritis, BMI 27+.

    10 sites in California
    • Medvin Clinical Research - Apple Valley, Apple Valley. 909-581-8477
    • Medvin Clinical Research - Covina, Covina. 626-869-5730
    • Newport Huntington Medical Group, Huntington Beach. 714-378-2440
    • Purushotham & Akther Kotha MD, Inc, La Mesa. 619-229-1995 x208
    • Medvin Clinical Research - Riverside, Riverside. (951) 672-1866
    • Rheumatology Center of San Diego, San Diego
    • Providence Saint John's Medical Foundation, Santa Monica
    • Medvin Clinical Research - Temecula, Temecula. 9516525000
    • Medvin Clinical Research - Tujunga, Tujunga. 8182652250
    • Medvin Clinical Research - Whittier, Whittier. 5627586600

  2. A Phase 4, Prospective, Open-Label, Single Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab

    Phase 4. Run by Eli Lilly and Company. Registry number NCT06857942.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people calm psoriasis.

    Who can join. Adults 18+, have psoriasis, BMI 27+.

    4 sites in California

  3. Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide

    Phase 4. Run by Stanford University. Registry number NCT06657209.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 30 to 70, have type 2 diabetes, BMI 19+.

    2 sites in California

    • Stanford University, Palo Alto. 408-896-0134
    • Stanford University, Clinical and Translational Research Unit (CTRU), Stanford. 408-896-0134

  4. PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

    Phase 4. Run by Brigham and Women's Hospital. Registry number NCT05390892.

    A study testing whether a GLP-1 medicine, semaglutide, can help people lower blood sugar.

    Who can join. Adults 40 to 80, have type 2 diabetes.

    1 site in California

    • Eastside Clinical Research Associates, Los Angeles. 323-261-4706

  5. Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT

    Phase 4. Run by Matthew J. Budoff. Registry number NCT05708859.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 40 to 80, have type 2 diabetes, BMI 25+.

    1 site in California

    • Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center (The Lundquist Institute), Torrance. 310-222-4107

  6. Restoring Facial Volume After GLP-1 Weight Loss With Radiesse

    Phase 4. Run by Kalpna Kay Durairaj, MD, FACS. Registry number NCT07419854.

    A study listed on ClinicalTrials.gov.

    1 site in California

    • K. Kay Durairaj, MD, A Medical Corp., Pasadena. 8183167033

  7. LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced

    Phase 3. Run by Boehringer Ingelheim. Registry number NCT06632444.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH) with liver scarring (fibrosis).

    25 sites in California

  8. LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

    Phase 3. Run by Boehringer Ingelheim. Registry number NCT06632457.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH), BMI 25+.

    16 sites in California

  9. A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

    Phase 3. Run by Eli Lilly and Company. Registry number NCT07165028.

    A study testing whether a GLP-1, GIP and glucagon medicine from Lilly, retatrutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (MASLD), BMI 25+.

    14 sites in California

  10. A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

    Phase 3. Run by Boehringer Ingelheim. Registry number NCT07754461.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    12 sites in California

  11. A Clinical Study to Compare Efficacy and Safety of Two Different Doses of CagriSema and Semaglutide in Participants With Obesity

    Phase 3. Run by Novo Nordisk A/S. Registry number NCT07564414.

    A study testing whether a study medicine from Novo Nordisk, cagrisema, can help people with type 2 diabetes lose weight.

    Who can join. Adults 18+, have obesity, BMI 35+.

    11 sites in California
    • Headlands Research California, LLC, Escondido
    • Neighborhood Healthcare, Escondido
    • Diabetes & Endocrine Specialists - La Mesa, La Mesa
    • Clinical Trials Research_Sacramento, Lincoln
    • Loma Linda University Faculty Medical Clinics, Loma Linda
    • Pacific Clinical Studies, Los Alamitos
    • Valley Clinical Trials, Northridge
    • Desert Oasis Healthcare, Palm Springs
    • Linda Vista Health Care Ctr, San Diego
    • Velocity Clin Res - Van Nuys, Van Nuys
    • Flourish Research - CA, Walnut Creek

  12. A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron

    Phase 3. Run by AstraZeneca. Registry number NCT07662213.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    7 sites in California
    • Research Site, Covina
    • Research Site, Encinitas
    • Research Site, Garden Grove
    • Research Site, Loma Linda
    • Research Site, Long Beach
    • Research Site, Pomona
    • Research Site, Sacramento

  13. A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

    Phase 3. Run by Eli Lilly and Company. Registry number NCT06672549.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

    Who can join. Children and teens 6 to 17, have obesity.

    5 sites in California
    • Loma Linda University School of Medicine, Loma Linda
    • Childrens Hospital of Los Angeles, Los Angeles
    • UCLA Mattel Children's Hospital, Los Angeles
    • Children's Hospital of Orange County - Orange, Orange
    • Carey Chronis MD Pediatric, Infant and Adolescent Medicine, Oxnard. 805-483-1185 x.947

  14. Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

    Phase 3. Run by Eli Lilly and Company. Registry number NCT07223593.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people improve blood flow in the legs.

    Who can join. Adults 18+, have peripheral artery disease (poor blood flow in the legs), BMI 23+.

    5 sites in California

  15. A Phase 3, Open-label Trial to Evaluate the Efficacy, Safety and Tolerability of Switching From the Glucagon-like Peptide-1

    Phase 3. Run by Amgen. Registry number NCT07575399.

    A study testing whether a study medicine from Amgen, Maridebart Cafraglutide, can help people lose weight.

    Who can join. Adults 18+, have obesity or are overweight, BMI 25+.

    5 sites in California
    • Desert Oasis Healthcare Medical Group, Palm Springs
    • Inland Empire Liver Foundation, Rialto
    • Peninsula Research Associates, Rolling Hills Estates
    • Apex Clinical Research, San Diego
    • Southern California Clinical Research, Santa Ana

  16. Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative

    Phase 3. Run by Eli Lilly and Company. Registry number NCT06937086.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with ulcerative colitis calm gut inflammation.

    Who can join. Adults 18 to 70, have ulcerative colitis, BMI 27+.

    4 sites in California

    • Smart Cures Clinical Research, Anaheim
    • Cedars-Sinai Medical Center, Beverly Hills. 310-423-4100
    • United Medical Doctors - Los Alamitos, Los Alamitos. 562-430-4449
    • California Medical Research Associates, Northridge. 818-349-1979

  17. Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity

    Phase 3. Run by Eli Lilly and Company. Registry number NCT06937099.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with Crohn's disease calm gut inflammation.

    Who can join. Adults 18 to 70, have Crohn's disease, BMI 27+.

    4 sites in California

    • Smart Cures Clinical Research, Anaheim
    • Cedars-Sinai Medical Center, Beverly Hills. 310-423-4100
    • United Medical Doctors - Los Alamitos, Los Alamitos. 562-430-4449
    • California Medical Research Associates, Northridge. 818-349-1979

  18. Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH

    Phase 3. Run by Altimmune, Inc. Registry number NCT07795164.

    A study testing whether a GLP-1 and glucagon medicine from Altimmune, pemvidutide, can help people reduce liver fat.

    Who can join. Adults 18 to 75, have fatty liver disease (also called MASH or NASH), BMI 23+.

    4 sites in California

    • Altimmune Clinical Study Site, Fountain Valley
    • Altimmune Clinical Study Site, Fresno
    • Altimmune Clinical Study Site, Gardena
    • Altimmune Clinical Study Site, Long Beach

  19. A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

    Phase 3. Run by Eli Lilly and Company. Registry number NCT07202884.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people reduce bladder leaks.

    Who can join. Adults 18+, women only, have stress urinary incontinence (bladder leaks), BMI 27+.

    3 sites in California

    • Matrix Clinical Research, Los Angeles. 310-424-5922
    • Alarcon Urology Center, Montebello
    • Prestige Medical Group, Tustin

  20. Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE)

    Phase 3. Run by VA Office of Research and Development. Registry number NCT07218354.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with alcohol use disorder drink less.

    Who can join. Adults 18 to 80, have alcohol use disorder, BMI 21+.

    3 sites in California

    • VA Long Beach Healthcare System, Long Beach, CA, Long Beach. 562-826-8000
    • VA Palo Alto Health Care System, Palo Alto, CA, Palo Alto. 650-493-5000
    • VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles. 310-268-3528
The other 31 studies recruiting in California

  1. A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use

    Phase 3. Run by Vanda Pharmaceuticals. Registry number NCT07446439.

    A study testing whether an investigational medicine from Vanda Pharmaceuticals, tradipitant, can help people reduce nausea and vomiting.

    Who can join. Adults 18 to 65, have nausea and vomiting, BMI 25+.

    3 sites in California

  2. Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

    Phase 3. Run by Novo Nordisk A/S. Registry number NCT07770841.

    A study testing whether a GLP-1 medicine from Novo Nordisk, semaglutide, can help people lose weight.

    Who can join. Adults 18+, are overweight, BMI 27+.

    3 sites in California

    • Headlands Research California, LLC, Escondido
    • National Research Institute - Huntington Park, Huntington Park
    • Los Angeles Institute for Metabolic Research, Los Angeles

  3. A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

    Phase 3. Run by Eli Lilly and Company. Registry number NCT06439277.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people lose weight.

    Who can join. Children and teens 12 to 17, have obesity.

    2 sites in California

    • Children's Hospital Los Angeles, Los Angeles
    • Sutter Valley Medical Foundation (SVMF) Pediatric Endocrinology, Sacramento

  4. A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

    Phase 3. Run by Eli Lilly and Company. Registry number NCT07153471.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people ease joint pain.

    Who can join. Adults 18+, have osteoarthritis (joint pain), BMI 27+.

    2 sites in California

  5. Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living

    Phase 3. Run by Kailera. Registry number NCT07284979.

    A study testing whether an investigational medicine from Kailera, KAI-9531, can help people lose weight.

    Who can join. Adults 18+, have obesity, BMI 35+.

    2 sites in California

    • Kailera Clinical Site, Northridge
    • Kailera Clinical Site, Oceanside

  6. A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

    Phase 3. Run by Eli Lilly and Company. Registry number NCT06672939.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

    Who can join. Children and teens 12 to 17, have obesity.

    1 site in California

    • Carey Chronis MD Pediatric, Infant and Adolescent Medicine, Oxnard

  7. Early Reinitiation of Semaglutide Post-Sleeve Gastrectomy in Youth

    Phase 3. Run by Children's Hospital Los Angeles. Registry number NCT06934655.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with obesity lose weight.

    Who can join. Children and teens 12 to 18, have obesity, BMI 35+.

    1 site in California

    • Children's Hospital Los Angeles, Los Angeles

  8. A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

    Phase 3. Run by Novo Nordisk A/S. Registry number NCT07253285.

    A study testing whether a study medicine from Novo Nordisk, cagrilintide, can help people lose weight.

    Who can join. Children and teens 8 to 18, are overweight.

    1 site in California

    • Neighborhood Healthcare, Escondido

  9. A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

    Phase 2. Run by Novo Nordisk A/S. Registry number NCT07415954.

    A study testing whether an investigational medicine from Novo Nordisk, NNC0662-0419, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 75, have type 2 diabetes.

    6 sites in California
    • First Valley Medical Group, Lancaster
    • Torrance Clinical Research Institute, Inc., Lomita
    • Ark Clinical Research, Long Beach
    • Pacific Clinical Studies, Los Alamitos
    • Wetlin Research Associates, Inc., San Diego
    • Diablo Clinical Research, Inc., Walnut Creek

  10. A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity

    Phase 2. Run by Eli Lilly and Company. Registry number NCT06143956.

    A study testing whether an investigational medicine from Lilly, LY3305677, can help people lose weight.

    Who can join. Adults 18 to 75, have obesity, BMI 27+.

    4 sites in California

    • NorCal Medical Research, Inc, Greenbrae. 415-461-1585
    • Velocity Clinical Research, Huntington Park, Huntington Park. 323-588-1990
    • Peninsula Research Associates, Rolling Hills Estates. 310-265-1623
    • Diablo Clinical Research, Inc., Walnut Creek. 925-930-7267

  11. Phase 2 Randomized, Double-blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Icovamenib in Participants

    Phase 2. Run by Biomea Fusion Inc. Registry number NCT07502508.

    A study testing whether an investigational medicine from Biomea Fusion, icovamenib, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 70, have type 2 diabetes, BMI 25+.

    4 sites in California

    • Hope Clinical Research, Canoga Park
    • Ark Clinical Research, Long Beach
    • Catalina Research Institute, LLC, Montclair
    • Paradigm Clinical Research Centers, LLC, San Diego

  12. A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

    Phase 2. Run by Novo Nordisk A/S. Registry number NCT07668388.

    A study testing whether an investigational medicine from Novo Nordisk, UBT251, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 75, have type 2 diabetes.

    4 sites in California

    • Ark Clinical Research, Fountain Valley
    • Ark Clinical Research, Long Beach
    • Los Angeles Institute for Metabolic Research, Los Angeles
    • Catalina Research Institute, LLC, Montclair

  13. A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living

    Phase 2. Run by Novo Nordisk A/S. Registry number NCT06717698.

    A study testing whether an investigational medicine from Novo Nordisk, NNC0519-0130, can help people with chronic kidney disease protect their kidneys.

    Who can join. Adults 18+, have chronic kidney disease, BMI 27+.

    2 sites in California

    • N America Res Inst - San Dimas, San Dimas
    • NorCal Endocrinology and Internal Medicine, San Ramon

  14. A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD

    Phase 2. Run by Regeneron Pharmaceuticals. Registry number NCT07527910.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people reduce liver fat.

    Who can join. Adults 18 to 75, have fatty liver disease (MASLD), BMI 30+.

    2 sites in California

    • Southern California Research Center, Coronado
    • California Liver Research Institute, Pasadena

  15. A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

    Phase 2. Run by Novo Nordisk A/S. Registry number NCT07639021.

    A study testing whether an investigational medicine from Novo Nordisk, NNC0662-0419, can help people lose weight.

    Who can join. Adults 18+, have obesity, BMI 30+.

    2 sites in California

    • FDRC, Costa Mesa
    • Los Angeles Institute for Metabolic Research, Los Angeles

  16. Sit Less, Interact and Move More (SLIMM) 2 Study

    Phase 2. Run by Srinvasan Beddhu. Registry number NCT05173714.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with chronic kidney disease protect their kidneys.

    Who can join. Adults 20+, have chronic kidney disease.

    1 site in California

  17. Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity

    Phase 2. Run by Stanford University. Registry number NCT05912621.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people lose weight.

    Who can join. Adults 18 to 70, have obesity, BMI 27+.

    1 site in California

    • Clinical and Translational Research Unit, Palo Alto. 650-888-0144

  18. A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

    Phase 2. Run by Eli Lilly and Company. Registry number NCT06897475.

    A study testing whether an investigational medicine from Lilly, LY3457263, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 75, have type 2 diabetes, BMI 27+.

    1 site in California

  19. Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease

    Phase 2. Run by Washington University School of Medicine. Registry number NCT06976853.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with Crohn's disease calm gut inflammation.

    Who can join. Adults 18 to 80, have Crohn's disease, BMI 25+.

    1 site in California

  20. Tirzepatide for Alcohol Use Disorder

    Phase 2. Run by University of Southern California. Registry number NCT06994338.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with alcohol use disorder drink less.

    Who can join. Adults 21 to 65, have alcohol use disorder, BMI 27+.

    1 site in California

    • Keck School of Medicine, University of Southern California, Los Angeles. 2139620698

  21. A Phase II Randomized Study of Interventions for Metabolic Protection Against Cardiometabolic Toxicity During Androgen

    Phase 2. Run by City of Hope Medical Center. Registry number NCT07202247.

    A study of a GLP-1 and GIP medicine, tirzepatide, in people with prostate cancer.

    Who can join. Adults 30 to 79, have prostate cancer, BMI 27+.

    1 site in California

  22. Glutide for Ending Methamphetamine

    Phase 2. Run by San Francisco Department of Public Health. Registry number NCT07204249.

    A study of a GLP-1 medicine, semaglutide, in people with methamphetamine dependence.

    Who can join. Adults 18 to 65, have methamphetamine dependence, BMI 25+.

    1 site in California

    • Center on Substance Use and Health, San Francisco. 6282176235

  23. Multi-Site Trial of Tirzepatide for Smoking Cessation

    Phase 2. Run by University of Southern California. Registry number NCT07602699.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people quit smoking.

    Who can join. Adults 21 to 65, are trying to quit smoking, BMI 25+.

    1 site in California

    • Keck School of Medicine, University of Southern California, Los Angeles. 213-962-0698

  24. Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes

    Phase 2. Run by Regeneron Pharmaceuticals. Registry number NCT07685808.

    A study testing whether a GLP-1 and GIP medicine from Regeneron Pharmaceuticals, olatorepatide, can help people lose weight.

    Who can join. Adults 18+, have obesity or are overweight, BMI 27+.

    1 site in California

    • Diablo Clinical Research - Flourish Research, Walnut Creek

  25. A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type

    Phase 2. Run by Antag Therapeutics. Registry number NCT07724340.

    A study testing whether an investigational medicine from Antag Therapeutics, AT673, can help people who are overweight lower blood sugar and lose weight.

    Who can join. Adults 18+, have type 2 diabetes, BMI 27+.

    1 site in California

  26. Investigation of the Effect of Fasting Duration and Temporary Withholding of GLP-1 RAs on Retained Gastric Contents

    Phase 1. Run by Novo Nordisk A/S. Registry number NCT07225816.

    A study testing whether a GLP-1 medicine from Novo Nordisk, semaglutide, can help people lose weight.

    Who can join. Adults 18+, have obesity, BMI 25+.

    1 site in California

    • Altasciences Clinical LA, Inc., Cypress

  27. Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse

    Phase 1. Run by Novo Nordisk A/S. Registry number NCT07607587.

    A study testing whether a study medicine from Novo Nordisk, cagrilintide, can help people lose weight.

    Who can join. Adults 18+, have obesity, BMI 30+.

    1 site in California

    • Diablo Clinical Research, Inc., Walnut Creek

  28. Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects

    Run by University of California, Los Angeles. Registry number NCT05419726.

    A study testing whether a GLP-1 medicine, semaglutide, can help people lose weight.

    Who can join. Adults 18+, have obesity.

    1 site in California

    • UCLA Health, Los Angeles

  29. Diabetes-Centered Evaluation of Revascularization Strategy of Functional and Imaging-CombiNEd State-of-the-Art Percutaneous

    Run by Duk-Woo Park, MD. Registry number NCT05831085.

    A study in people with coronary artery stenosis.

    Who can join. Adults 20+, have coronary artery stenosis.

    1 site in California

    • Palo Alto VA Medical Center, Palo Alto

  30. Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor

    Run by Cytrellis Biosystems, Inc. Registry number NCT07224880.

    A study listed on ClinicalTrials.gov.

    1 site in California

  31. A Randomized, Triple-blind, Placebo-controlled Study to Evaluate the Effects of a Supplement on Nutrient Gaps and Gut Health

    Run by Athletic Greens International. Registry number NCT07437911.

    A study listed on ClinicalTrials.gov.

    Who can join. Adults 18 to 59, BMI 20+.

    1 site in California

Source: ClinicalTrials.gov, the federal registry, read September 4, 2026. Open a study's registry record before you call: it can close to new participants at any time. GLP Chart does not enroll anyone, is not paid for clinical-trial referrals and has no relationship with any sponsor or site on this page.

Screening for a study can take weeks. If you need the drug now, Strut Health is the cheapest cash route on the chart, from $149 a month. That price buys compounded semaglutide, a pharmacy-made version that is not FDA-approved and is not Wegovy, Ozempic, Zepbound or Mounjaro.

Visit Strut Health ↗

Clinical trials by state

Every state with a GLP-1 study recruiting today. 48 of them.

John Samaras, editor of GLP Chart
John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this siteLinkedInContact
Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.